
In today’s briefing:
- Hang Seng Bank (11 HK): HSBC (5 HK)’s Scheme Vote on 8 January
- BYD (1211 HK) Tactical Outlook: Time To Go LONG? Not Yet.
- B&K (华芢生物科技) IPO: Weak Fundamentals
- Baidu: Inside the AI Marketing Engine Delivering Triple-Digit Growth!
- CSPC Innovation (300765 CH) A/H Listing: Shifting Focus to Biopharma Augurs Well
- Tencent Music Entertainment Group: How Live Events & Fan Economies Are Reshaping Growth!
- PDD Holdings: Reinventing E-Commerce Through Merchant Support & Agricultural Innovation
- Pre-IPO InSilico Medicine (PHIP Updates) – Some Points Worth the Attention
- JD.com: A Robust Competitive Positioning Anchored in Proprietary Logistics and Ecosystem Expansion!
- Primer: TI Cloud (2167 HK) – Dec 2025

Hang Seng Bank (11 HK): HSBC (5 HK)’s Scheme Vote on 8 January
- Hang Seng Bank (11 HK)’s IFA considers HSBC Holdings (5 HK)’s scheme privatisation offer of HK$155 per share to be fair and reasonable.
- The key condition is scheme approval by at least 75% disinterested shareholders (<10% disinterested shareholders’ rejection). The scheme vote remains low risk.
- The offer is attractive compared to peer multiples and privatisation precedents. This is done. At the current price and for a 4 February payment, the gross/annualised spread is 1.0%/7.1%.
BYD (1211 HK) Tactical Outlook: Time To Go LONG? Not Yet.
- BYD (1211 HK) has been downtrending for a while, a speculative LONG positioning starts to become attractive for some, but according to our model the short-term upside is limited.
- The stock is pulling back this week, second consecutive week down, this insight will try to identify price zones where to buy the stock and where to exit / hedge.
- BYD could be held past our suggested profit target at 101.8 (in case the next bear rally it’s not just a bear-rally), but time-wise it’s a 2 weeks rally, tops.
B&K (华芢生物科技) IPO: Weak Fundamentals
- B&K, a China-based clinical stage biotech company, launched its IPO to raise at USD 774 million via a Hong Kong listing.
- In this note, we look at its fundamentals briefly, including its core products and its management team.
- We deem the fundamentals of the deal weak and will avoid the deal.
Baidu: Inside the AI Marketing Engine Delivering Triple-Digit Growth!
- Baidu’s financial performance for the third quarter of 2025 highlights both strengths and challenges.
- The company reported total revenues of RMB 31.2 billion, which represents a 7% decline year-over-year.
- Baidu Core, a significant segment, showed revenue at RMB 24.7 billion, aligning with this downward trend.
CSPC Innovation (300765 CH) A/H Listing: Shifting Focus to Biopharma Augurs Well
- CSPC Innovation Pharmaceutical-A (300765 CH) has applied for H share listing on the Hong Kong Stock Exchange, with CITIC Securities being the sole sponsor to the issue.
- The company intends to raise fund for financing biopharmaceuticals R&D, acquisitions of companies or drug assets to expand product portfolio, and commercialization of approved products and late-stage product candidates.
- CSPC Innovation shares have been listed in China since 2019. After strong run-up from September 2023 to June 2025 (shares jumped 5x), shares fell 43% over the last six months.
Tencent Music Entertainment Group: How Live Events & Fan Economies Are Reshaping Growth!
- Tencent Music Entertainment Group reported strong third-quarter results in 2025, driven by significant growth in its online music business.
- Total revenues grew by 21% year-over-year to RMB 8.5 billion, with online music revenues increasing by over 27% to RMB 7 billion.
- The growth in music subscription revenues was notable, with a 70% year-on-year increase to RMB 4.5 billion, propelled by a steady rise in paying users and enhancements in ARPPU, which reached RMB 11.9 compared to RMB 10.8 from the previous year.
PDD Holdings: Reinventing E-Commerce Through Merchant Support & Agricultural Innovation
- PDD Holdings Inc. has presented a performance in the third quarter of 2025 that reflects the challenges and opportunities in the evolving e-commerce landscape.
- The company reported revenues of RMB 108.3 billion, marking a 9% year-over-year increase, fueled by growth in online marketing services and transaction revenues.
- However, growth remains pressured amidst an intensely competitive environment in the e-commerce sector.
Pre-IPO InSilico Medicine (PHIP Updates) – Some Points Worth the Attention
- Although Insilico’s development direction is AI-Biotech, its “genes” don’t support the continuous promotion of drug R&D into later clinical stages. It’s more realistic to sell early-stage candidates and collect cash.
- Relying solely on AI pharmaceuticals cannot quickly enter the commercialization stage of innovative drugs. In fact, capital has seen the truth and pharmaceutical companies also doubt its real value.
- Insilico in on the right path in terms of business model.If InSilico has the opportunity to develop blockbuster drugs, its future valuation can easily lead QuantumPharm by a large margin.
JD.com: A Robust Competitive Positioning Anchored in Proprietary Logistics and Ecosystem Expansion!
- JD.com’s third-quarter 2025 earnings indicate a blend of moderate growth and inherent challenges.
- The company reported a 15% year-on-year increase in total revenues, maintaining a double-digit growth pattern.
- This uptick was driven by gains in general merchandise and marketplace and marketing revenues.
Primer: TI Cloud (2167 HK) – Dec 2025
- TI Cloud is a leading cloud-native customer contact solutions provider in China, demonstrating a significant financial turnaround with strong revenue growth and a return to profitability in the latest fiscal year.
- The company is well-positioned to capitalize on the rapid growth of China’s cloud computing market, which is driven by nationwide digital transformation initiatives and increasing AI adoption.
- Valuation appears attractive relative to peers, especially considering its high growth and strong Smartkarma Smartscores across Value, Dividend, Growth, and Momentum. However, the stock has shown high volatility.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

